Customize
Quick Links
Specialties

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps highlight key elements of the Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better Outcomes online CME activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better Outcomes

Release Date: April 27, 2017
Expiration Date: April 27, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better Outcomes features case-based discussion of state-of-the-art therapy for patients with EGFR mutation-positive, non–small cell lung cancers (NSCLCs) through multiple lines of therapy. Interactive clinical vignettes are followed by short video interviews with leading lung cancer experts and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, including testing, treatment, and brain metastases, as well as questions commonly faced in the community oncology practice setting by physicians engaged in the care of patients with NSCLCs and EGFR mutations.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

CME/CE Activity Table of Contents

  • First-Line Therapy in EGFR Mutation-Positive Lung Cancer
  • Biopsy for Acquired Resistance
  • Leptomeningeal Disease
  • Second-Line Therapy
  • Subsequent Therapy

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with lung cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail evidence that underlies the application of optimized front-line strategies to manage EGFR-mutated advanced NSCLC
  • Describe methods to optimize EGFR subtyping and emerging technologies that can practically facilitate tumor testing, as well as overcome inherent challenges to optimized testing in community settings where advanced NSCLC is managed
  • Explain how to optimize the timing of clinical interventions in relapsed advanced NSCLC settings and the trial evidence that informs decision-making to treat patients with EGFR-TKI resistance
  • Address treatment-related toxicities and methods to optimize the management of central nervous system metastases in the care of patients with advanced NSCLC

Faculty, Staff, and Planners' Disclosures

Faculty

Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosure: PUMA, Pfizer, Genentech; Consultant: AstraZeneca, ARIAD, Roche/Genentech, Array

Alexander Drilon, MD
Clinical Director, Developmental Therapeutics
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Other Support: Genentech, Ariad, Ignyta, LOXO, Blueprint

Balazs Halmos, MD
Professor of Clinical Medicine
Section Chief Thoracic Oncology and Director
Clinical Cancer Genomics
Albert Einstein College of Medicine
Einstein Montefiore Cancer Center

Disclosure: Grant/Research Support: Mirati, Eli Lilly, Merck, Boehringer Ingelheim; Consultant: FoundationOne, AstraZeneca, Boehringer Ingelheim, Genentech, Pfizer, Eli Lilly.

Helena Yu, MD
Assistant Attending
Memorial Sloan Kettering Cancer Center
New York, NY
 
 

Disclosure: Consultant: Eli Lilly, Boehringer Ingelheim; Grant/Research Support: (paid to institution) Astellas, AstraZeneca, Eli Lilly.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise






Become a Member

Forgot Password?
Filter By